Slide background

think antibodyomes!

MemoMAB™

 

Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis (introductory video).

Its MemoMABTM platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’s immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.

The business strategy of MEMO is the discovery of therapeutic antibody candidates and target discovery for antibody and vaccine development. MemoMABTM is deployed in proprietary antibody lead discovery programs and is made available in collaborations.

Learn more about antibodies, the human antibody library (discovery), immune repertoire analysis and antibody discovery deploying the huMemoMAB™ and rbMemoMAB™ platforms, respectively.

 

 

m

Discover the MemoMAB™ toolbox

 

Human immune repertoires

huMemo

 Antibody discovery from a human cognate antibody library.

>>

huMemo

 Immune repertoire analysis in humans for both healthy individuals and for patients.

>>

Animal immunization

rbMemo

Classical antibody discovery taking advantage of the superior rabbit immune response in combination with the highly efficient rbMemoMAB™ technology.

>>

m

Latest News

Top100 Best Swiss Startups 2017: MEMO is in the Top5 Biotech

Memo Therapeutics made it to the top 100 of Swiss startups for the third time in a row and is …


Posted in 2017, News, Uncategorized

|
Comments Off on Top100 Best Swiss Startups 2017: MEMO is in the Top5 Biotech

New KTI/CTI project for oncology targets

Memo Therapeutics AG was awarded a new CTI grant
MEMO has secured a third CTI …


Posted in 2017, News

|
Comments Off on New KTI/CTI project for oncology targets

First Human Antibodies

Memo Therapeutics AG announces proof of concept of its huMemoMABTM antibody technology platform
 
Basel/Zurich, Switzerland, May 23, …


Posted in 2017, News

|
Comments Off on First Human Antibodies

>>